InvestSMART

Lumos Diagnostics Holdings Limited (ASX:LDX)

ALERT: Price-sensitive ASX Announcement for LDX
Current share price for LDX : $0.083 -0.022 (-20.95%)+
Announcement
Release
4 Aug 2026 9:04AM
Price at Release
$0.105
Full Release
download
Summary
Lumos Diagnostics Holdings Limited announced receiving a US$767,800 purchase order from PHASE Scientific for FebriDx, a rapid test for diagnosing febrile respiratory infections. The order, slated for delivery by October 2026, is part of a larger US$5.0 million prepayment milestone following FebriDx's CLIA waiver approval by the U.S. FDA in March 2026. The purchase order contributes towards Lumos's Year 1 order quantity under the distribution agreement, with CEO Doug Ward highlighting the significance of this order in preparing U.S. healthcare providers for the flu season.
Key Points
  • Lumos Diagnostics received a US$767,800 purchase order from PHASE Scientific for FebriDx.
  • Product delivery will be fulfilled between now and October 2026.
  • This order is part of a US$5.0 million prepayment milestone after FebriDx received CLIA waiver from the U.S. FDA.
  • The order satisfies part of the Year 1 minimum order quantity commitment.
  • Doug Ward, CEO, expressed optimism about the commercialisation of FebriDx, especially for the upcoming flu season in the U.S.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.